Clinical Hospital № 3
Yaroslavl, 150007, Russia
NCT Number: NCT04101370
Bioequivalence Study of 2 formulation of bosentan (Bosentan GEROPHARM vers. Tracleer® Actelion)
Looking for future studies?
Notify Me18 year–45 year
Male
Interventional
Phase 1
Yaroslavl, 150007, Russia
Study to evaluate the bioequivalence of orally administered bosentan preparations, immediate release tablets, 125 mg in normal healthy subjects under fasting conditions
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
Other names: bosentan
Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition
Other names: bosentan
Time frame: 0 hours (pre-dose), as well as at 0.5, 1, 1.5, 2, 2.5, 3, 3,5, 3,75, 4, 4.25, 4.5, 4.75, 5, 6, 8, 10, 12, 14 and 24 hour post-dose.
Pharmacokinetics of bosentan by Assessment of Observed Maximum Plasma Concentration (Cmax)
Time frame: 0 hours (pre-dose), as well as at 0.5, 1, 1.5, 2, 2.5, 3, 3,5, 3,75, 4, 4.25, 4.5, 4.75, 5, 6, 8, 10, 12, 14 and 24 hour post-dose.
Pharmacokinetics of bosentan by Assessment of Area Under the Curve From Time Zero Extrapolated to "t" (AUC(0-t))
Geropharm
Industry
Two-way Crossover, Open-label, Single-dose, Bioequivalence Study of Bosentan (LLC "GEROPHARM", Russia) 125 mg Tablets Immediate Release (IR )Versus Tracleer® (Actelion Pharmaceuticals Ltd., Switzerland) 125 mg Tablets IR in Normal Healthy Subjects Under Fasting Conditions
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03452306
Behavior, Bioequivalence
Yaroslavl, Russia
View Trial DetailsNCT03458208
Behavior, Bioequivalence
Yaroslavl, Russia
View Trial DetailsNCT07698288
Bioequivalence
Mexico City, Mexico
View Trial DetailsNCT06987773
Bioequivalence
Toronto, Ontario, Canada
View Trial Details